Breakthrough in Zika virus vaccine

December 12, 2019

Researchers from the University of Adelaide have made significant advances in developing a novel vaccine against Zika virus, which could potentially lead to global elimination of the disease.

The virology team, led by Professor Eric Gowans and Dr Branka Grubor-Bauk - based at the Basil Hetzel Institute for Translational Health Research and supported by The Hospital Research Foundation - has developed a vaccine that prevents Zika infection in pre-clinical models of the disease.

Their findings have been published today in the leading international journal Science Advances.

Zika is a mosquito-transmitted 'flavivirus' which can cause microcephaly (a birth defect where a baby's head is significantly smaller than expected) and severe birth defects in infants born to infected mothers.

The introduction of an effective vaccine for Zika will prevent infection of pregnant women and the resultant congenital effects in the unborn child.

Dr Grubor-Bauk, senior research officer with the Adelaide Medical School, said the team had developed a novel vaccine against Zika that proved effective in mouse models.

"This is the first vaccine study that shows that a T cell-based vaccine can confer protection against a systemic Zika infection,'' she said.

"Our vaccine offers an advantage over other vaccines in development by eliminating the ongoing concerns in the field about enhancement of infection following exposure to dengue virus. This finding demonstrates for the first time that protective T cell vaccines against Zika are achievable.

"Zika virus is extremely detrimental if you're pregnant and there has been no therapy or vaccine available to date. If we can progress this work and immunise women who are of reproductive age and most at risk, we can stop the devastating effects of Zika infection in pregnancy and make a huge difference to the health of the global community."

This research, which has been years in the making, has progressed to this significant stage thanks to funding from National Foundation for Medical Research and Innovation (NFMRI) and ongoing funding from The Hospital Research Foundation.

The work was done in collaboration with eminent global vaccine researcher Prof Dan Barouch, Director of Harvard Medical School's Centre for Virology and Vaccine Research (CVVR) at Beth Israel Deaconess Medical Centre; as well as Adelaide's Prof Sarah Robertson, Director of the Robinson Research Institute, University of Adelaide; and other scientists from the universities of Adelaide, South Australia and Flinders.

"The next steps are to advance the vaccine to being ready for Phase I human clinical trials. This involves further pre-clinical studies which are vitally important to identify the most effective dosing and demonstrate protection against Zika infection in different pre-clinical models of the disease," Dr Grubor-Bauk said.

"The goal is to de-risk and create an attractive technology with a strong IP position, for licensing or co-development with a commercial partner.

"We are grateful to The Hospital Research Foundation which has been instrumental in their support of our research over this time. We could not have reached this point without them."

The findings of this study will also greatly inform other research in the development of flavivirus vaccines by shifting the focus of vaccine development from viral envelope and antibody-based vaccines to T-cell based vaccines.
-end-


University of Adelaide

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.